Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below Fifty Day Moving Average – Here’s Why

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.24 and traded as low as $1.99. Aytu BioPharma shares last traded at $1.99, with a volume of 61,012 shares.

Analyst Ratings Changes

Several research firms recently weighed in on AYTU. Ascendiant Capital Markets increased their target price on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Finally, Zacks Research upgraded shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Aytu BioPharma currently has a consensus rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Trading Down 2.9%

The firm has a fifty day moving average of $2.24 and a 200-day moving average of $2.35. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The stock has a market capitalization of $21.35 million, a price-to-earnings ratio of -0.43 and a beta of 0.26.

Institutional Investors Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Aytu BioPharma in the 2nd quarter valued at about $49,000. Rothschild Wealth LLC purchased a new position in Aytu BioPharma during the 4th quarter worth approximately $52,000. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma during the 3rd quarter valued at about $58,000. XTX Topco Ltd purchased a new position in shares of Aytu BioPharma during the 4th quarter valued at $67,000. Finally, DRW Securities LLC acquired a new stake in Aytu BioPharma during the fourth quarter valued at $76,000. 33.49% of the stock is owned by institutional investors and hedge funds.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.